Table 1.

Treatment schedule

Induction treatment
Regimen: CVRDd to maximum response (or a maximum of 6 cycles of bortezomib)			Cycle duration: 21 days
Drug	Dose	Route	Days
Cyclophosphamide	500 mg	PO	1 and 8
Bortezomib	1.3 mg/m2	SC	1, 4, 8, 11
Lenalidomide	25 mg	PO	1–14
Daratumumab	16 mg/kg (actual body weight)	IV	1, 8, 15† (cycles 1 and 2)
			1 only (cycle 3 onwards)
Dexamethasone*	20–40 mg	PO/IV	1, 4, 8, 11
Autologous stem cell transplant (ASCT) Cyclophosphamide and GCSF mobilisation is recommended
Regimen: bortezomib HD-MEL+ASCT
Drug	Dose	Route	Days
Melphalan	200 mg/m2	IV	−1
Bortezomib	1.3 mg/m2	SC	−1, (8–18 hours post Melphalan)
Autologous stem cell return	IV		0
Bortezomib	1.3 mg/m2	SC	+5, +14, then weekly to consolidation 1
Consolidation treatment 1 To begin between 100 and 120 days post ASCT
Regimen: VRDd×6 cycles*		Cycle duration: 28 days
Drug	Dose	Route	Days
Bortezomib	1.3 mg/m2	SC	1, 8,15, 22
Lenalidomide	25 mg	PO	1–21
Daratumumab	16 mg/kg (actual body weight)	IV	1
Dexamethasone*	20–40mg	PO/IV	1, 8,15†, 22
Consolidation treatment 2
Regimen: VRD×12 cycles*		Cycle duration: 28 days
Drug	Dose	Route	Days
Bortezomib	1.3 mg/m2	SC	1, 8,15
Lenalidomide	25 mg	PO	1–21
Daratumumab	16 mg/kg (actual body weight)	IV	1
Maintenance treatment
Regimen: RD until progression		Cycle duration: 28 days
Drug	Dose	Route	Days
Lenalidomide	10 mg	PO	1–21
Daratumumab	16 mg/kg (actual body weight)	IV	1

*On days where participants receive dexamethasone 40 mg at site (i.e. predaratumumab infusion), dexamethasone must not be self-administered at home too.

†On day 15, participants will receive premed as per SPC (eg, methylprednisolone).

CVRDd, cyclophosphamide, bortezomib (Velcade), lenalidomide (Revlimid), daratumumab (Darzalex), dexamethasone; GCSF, granulyte colony-stimulating factor; HD-MEL, high dose melphalan; IV, intravenous; RD, lenalidomide, daratumumab; SC, subcutaneous; SPC, summary of product characteristics; VRD, bortezomib, lenalidomide, daratumumab; VRDd, bortezomib, lenaliomide, daratumumab, dexamethasone.